Startup profile · funding coverage
Gate Bioscience
Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.
Stage
series b
Status
private
Coverage
full
Why Gate Bioscience is interesting
Gate Bioscience's differentiated protein-secretion blockade attracted ARCH and a16z across a $60M Series A and $65M Series B.
Key facts
- Series A (2023): $60M co-led by Versant Ventures and a16z Bio + Health (/fund/andreessen-horowitz) with ARCH Venture Partners (/fund/arch-venture-partners) (BioCentury)
- Series B (2025): $65M with ARCH among existing investors (Gate Bio press)
Investors in our directory
Funds linked from Gate Bioscience's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Gate Bioscience
Funding context and why this company shows up in venture coverage.
Gate Bioscience develops oral small-molecule drugs using its Molecular Gate platform, which blocks secretion of disease-causing proteins — a differentiated approach from traditional intracellular enzyme inhibition.
Gate Bioscience's $60M Series A (2023) was co-led by a16z Bio + Health (/fund/andreessen-horowitz) and Versant Ventures, with ARCH Venture Partners (/fund/arch-venture-partners). ARCH re-upped in the $65M Series B (2025).
Gate Bioscience is at Series B based on its 2025 $65M round.
Many disease-causing proteins are secreted rather than intracellular. Gate's Molecular Gate mechanism targets that class with oral medicines — a novel modality with broad therapeutic potential.
No. Gate Bioscience remains a private company.
Last updated: 2026-07-24